Louvain, Belgium – Cancer is the major cause of death among men. Based on the current trends, scientists predict that, by about 2010, cancer will be the No. 1 cause of death for women as well. VIB scientists connected to the Katholieke Universiteit Leuven, in collaboration with the Flemish biotech company ThromboGenics, have been studying the anti-cancer action of anti-PLGF. This substance appears not only to be successful in the treatment of tumors for which the current therapies fail, but it also contributes to the greater effectiveness of existing chemotherapy, and still without side effects. Thus, anti-PLGF might possibly form the basis for a new treatment for cancer. This new finding, which is extremely important, was published in one of the most prestigious journals: CELL.
